# Vinay Prasad

Type: Person

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/vinay-prasad
Canonical HTML page: https://getlegalbrief.com/entity/vinay-prasad

## Timeline

- **2026-02-03**: Refusal to File — FDA's Vinay Prasad issues a formal refusal to review the flu vaccine application.
- **2025-11-10**: Grant Rescissions — The White House rescinds hundreds of millions in mRNA research funding.
- **2025-08-20**: Workaround Support — FDA officials reportedly signal acceptance of Moderna's alternative trial data submission.
- **2024-01-15**: Flu Vaccine Collaboration — Moderna begins working with the FDA on trial designs for its mRNA flu vaccine.
- **2021-08-01**: Peak Valuation — Moderna reaches a $200 billion market cap following global vaccine success.

## Recent coverage (1 stories)

### FDA Regulatory Shifts and Moderna's Flu Vaccine Setback Threaten Innovation
2026-03-16 00:09:34 · Sentiment: Negative · Impact: 8/10 · Sources: 2

The FDA's rare 'refusal to file' regarding Moderna's mRNA flu vaccine signals a pivot from pandemic-era collaboration to a more adversarial regulatory environment. This unpredictability, combined with rescinded federal grants and a 90% decline in market value, highlights the growing legal and compliance risks for biotech firms.
Full story: https://getlegalbrief.com/story/fda-moderna-regulatory-risk-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.